English, Article edition: Economic Impact of Aminoglycoside Toxicity and its Prevention Through Therapeutic Drug Monitoring Richard L. Slaughter; Diane M. Cappelletty

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94537
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Impact of Aminoglycoside Toxicity and its Prevention Through Therapeutic Drug Monitoring
Author
  • Richard L. Slaughter
  • Diane M. Cappelletty
Physical Description
  • article
Notes
  • Therapeutic drug monitoring (TDM) of aminoglycoside antibacterials with the goal of minimising toxicity and maximising effectiveness has become routine. Successful management of serious infections requires the ability to achieve therapeutic peak concentrations, while maintaining low trough concentrations will assist in avoiding nephrotoxicity. Reported nephrotoxicity rates range from 1.7 to 58% and depend on the definition used, the patient group studied, concomitant drug therapy used and whether TDM services have been provided. TDM services have been shown to reduce aminoglycoside nephrotoxicity. The costs of providing TDM averages $US301.87 (1997 values) per patient and the cost for each use of nephrotoxicity is estimated at $US4583 (1997 values). In order for the costs of providing a TDM service to 100 patients ($US30 187) to be offset by cost savings due to decreasing nephrotoxicity, the service would need to be able to reduce nephrotoxicity by 6.6%, resulting in a saving of $US30 248. The ability to achieve this saving is dependent on the characteristics of the population in which aminoglycoside therapy is used. In populations where high rates of nephrotoxicity (e.g. >15%) would be expected, TDM services are cost justified. In populations where nephrotoxicity is low (e.g. <5%), TDM service is not justified for this purpose. In order to provide a cost-efficient approach to TDM, resources should be focused on providing service to high risk patient groups.
  • Reviews-on-treatment, Aminoglycosides, Kidney-disorders, Adverse-reaction-monitoring, Pharmacoeconomics, Cost-analysis
  • RePEc:wkh:phecon:v:14:y:1998:i:4:p:385-394
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment